Refine by MP, party, committee, province, or result type.
Health committee Thank you, Madam Chair.
April 3rd, 2012Committee meeting
Paul Glover
Public Accounts committee We do a number of foreign inspections, and we also have what we call mutual recognition agreements, where we have gone through confidence-building and rather than constantly going all around the world, we work with our international partners and exchange information. For those th
March 29th, 2012Committee meeting
Paul Glover
Public Accounts committee Mr. Chair, I'll try to be as clear as I possibly can, perhaps it was my miscommunication. Sandoz has a plant in Boucherville, Quebec, and two in the U.S. The FDA inspected all of those. The FDA was concerned with what it saw in the Boucherville plant in Quebec, with respect to
March 29th, 2012Committee meeting
Paul Glover
Public Accounts committee No. We were monitoring and watching that. The ultimate issue, if I may, was a business decision by Sandoz, in terms of responding and how they chose to respond, that has resulted in this. They could have responded to both the FDA warning letter and to our reports differently tha
March 29th, 2012Committee meeting
Paul Glover
Public Accounts committee The drug companies supply us with adverse events from other jurisdictions. They also supply us with adverse events reported to them. We also take adverse events from physicians directly—there is a form that they fill out—and from individual patients themselves. So we get it fro
March 29th, 2012Committee meeting
Paul Glover
Public Accounts committee That goes back to the MedEffect and the Canadian adverse event reporting newsletter. We have several thousand people who subscribe to it.
March 29th, 2012Committee meeting
Paul Glover
Public Accounts committee It is on it.
March 29th, 2012Committee meeting
Paul Glover
Public Accounts committee Yes. We don't post those hundreds of thousands of adverse events. We sift through that information to what the real events are—what the things are that we've followed up on.
March 29th, 2012Committee meeting
Paul Glover
Public Accounts committee What we post is the specific summaries of those, as we've investigated them. Otherwise, you're swimming in a sea of data, with hundreds of thousands year after year.
March 29th, 2012Committee meeting
Paul Glover
Public Accounts committee Yes, and that is what is summarized in the adverse event newsletters, warnings to health professionals, etc.
March 29th, 2012Committee meeting
Paul Glover
March 29th, 2012Committee meeting
Paul Glover
Public Accounts committee We'll provide several links. We'll provide a link to all of the drugs that are available for sale in Canada. We'll also provide a link to our adverse events, the MedEffect, and Canadian adverse reaction newsletter. So you will have both those, all drugs and all adverse events, an
March 29th, 2012Committee meeting
Paul Glover
Public Accounts committee It is already shared with the public.
March 29th, 2012Committee meeting
Paul Glover
Public Accounts committee Once a product is on the market, adverse events are the most important signal for us. We follow those up very actively. To provide the committee with some specific numbers, there were over 30,000 domestic adverse events reported to Health Canada in the last year—that is in additi
March 29th, 2012Committee meeting
Paul Glover
Public Accounts committee Thank you very much, Mr. Chair, for the member's question. With respect to safety, first and foremost, the design of all clinical trials is subject to a review and approval by the department to ensure that the trial both achieves its objective in its design and that the patient'
March 29th, 2012Committee meeting
Paul Glover